These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 520684

  • 41. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA, King J, Law B, Mills E, Willems P.
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [Abstract] [Full Text] [Related]

  • 42. [Tetanus prevention with vaccine and with vaccine plus heterologous immune serum: serum antibody levels in the rabbit].
    Bistoni F, Mosci L, Vecchiarelli A, Marconi P, Pitzurra M.
    Ann Sclavo; 1977 May; 19(5):1006-12. PubMed ID: 616255
    [Abstract] [Full Text] [Related]

  • 43. High tetanus and diphtheria antitoxin concentrations in Finnish adults--time for new booster recommendations?
    Olander RM, Auranen K, Härkänen T, Leino T.
    Vaccine; 2009 Aug 27; 27(39):5295-8. PubMed ID: 19596410
    [Abstract] [Full Text] [Related]

  • 44. The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial.
    Newell KW, Dueñas Lehmann A, LeBlanc DR, Garces Osorio N.
    Bull World Health Organ; 1966 Aug 27; 35(6):863-71. PubMed ID: 5338377
    [Abstract] [Full Text] [Related]

  • 45. [Changes in anti-tetanus antibodies under sero-toxoid therapy. Study in 50 patients with tetanus].
    Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF.
    Nouv Presse Med; 1976 Mar 27; 5(13):847-50. PubMed ID: 1264625
    [Abstract] [Full Text] [Related]

  • 46. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.
    Vaccine; 2006 Jul 07; 24(27-28):5627-36. PubMed ID: 16740348
    [Abstract] [Full Text] [Related]

  • 47. [Split tetanus vaccine. Studies on its efficacy and tolerance as compared to adsorbed vaccine].
    Ambrosch F, Wiedermann G.
    Fortschr Med; 1984 Aug 16; 102(29-30):757-9. PubMed ID: 6500445
    [Abstract] [Full Text] [Related]

  • 48. Immunization against neonatal tetanus in New Guinea. Antitoxin response of pregnant women to adjuvant and plain toxoids.
    MacLennan R, Schofield FD, Pittman M, Hardegree MC, Barile MF.
    Bull World Health Organ; 1965 Aug 16; 32(5):683-97. PubMed ID: 5294183
    [Abstract] [Full Text] [Related]

  • 49. Active immunisation of horses against tetanus including the booster dose and its application.
    Liefman CE.
    Aust Vet J; 1981 Feb 16; 57(2):57-60. PubMed ID: 7259644
    [Abstract] [Full Text] [Related]

  • 50. Secondary response to boostering by purified aluminium-hydroxide-adsorbed tetanus anatoxin in aging and in aged adults.
    Solomonova K, Vizev S.
    Immunobiology; 1981 Feb 16; 158(4):312-9. PubMed ID: 7239554
    [Abstract] [Full Text] [Related]

  • 51. Lack of early antitoxin response to tetanus booster.
    Porter JD, Perkin MA, Corbel MJ, Farrington CP, Watkins JT, Begg NT.
    Vaccine; 1992 Feb 16; 10(5):334-6. PubMed ID: 1574917
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Immunity against tetanus and effect of revaccination 25-30 years after primary vaccination.
    Simonsen O, Kjeldsen K, Heron I.
    Lancet; 1984 Dec 01; 2(8414):1240-2. PubMed ID: 6150278
    [Abstract] [Full Text] [Related]

  • 54. [Tetanus antitoxin concentration in the serum of children and adolescents].
    Giesecke H, Baumert A.
    Z Gesamte Hyg; 1979 Mar 01; 25(3):257-60. PubMed ID: 442725
    [No Abstract] [Full Text] [Related]

  • 55. Immunization against neonatal tetanus in New Guinea. 5. Laboratory assayed potency of tetanus toxoids and relationship to human antitoxin response.
    Pittman M, Kolb RW, Barile MF, Hardegree MC, Seligmann EB, Maclennan R, Schofield FD.
    Bull World Health Organ; 1970 Mar 01; 43(3):469-78. PubMed ID: 5313001
    [Abstract] [Full Text] [Related]

  • 56. Reactions to tetanus toxoid.
    White WG, Barnes GM, Barker E, Gall D, Knight P, Griffith AH, Morris-Owen RM, Smith JW.
    J Hyg (Lond); 1973 Jun 01; 71(2):283-97. PubMed ID: 4515879
    [Abstract] [Full Text] [Related]

  • 57. Decline of tetanus antitoxin level with age in taiwan.
    Wu CJ, Ko HC, Lee HC, Tsai WC, Li MG, Pao YZ, Lee NY, Chang CM, Shih HI, Ko WC.
    J Formos Med Assoc; 2009 May 01; 108(5):395-401. PubMed ID: 19443293
    [Abstract] [Full Text] [Related]

  • 58. Benefits of immunization versus risk factors in tetanus.
    Rey M, Guillaumont P, d'Intignano BM.
    Dev Biol Stand; 1979 May 01; 43():15-23. PubMed ID: 520667
    [Abstract] [Full Text] [Related]

  • 59. Antibody response to successive booster doses of tetanus toxoid in adults.
    Trinca JC.
    Infect Immun; 1974 Jul 01; 10(1):1-5. PubMed ID: 4842700
    [Abstract] [Full Text] [Related]

  • 60. The standardization of Cl. perfringens antigens and antisera.
    Jansen BC.
    Dev Biol Stand; 1976 Jul 01; 32():35-44. PubMed ID: 187510
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.